Opus Genetics, Inc. (IRD)
| Market Cap | 157.93M +342.7% |
| Revenue (ttm) | 14.63M +74.6% |
| Net Income | -68.20M |
| EPS | -1.37 |
| Shares Out | 68.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 567,021 |
| Open | 2.400 |
| Previous Close | 2.400 |
| Day's Range | 2.220 - 2.440 |
| 52-Week Range | 0.650 - 3.050 |
| Beta | 0.59 |
| Analysts | Strong Buy |
| Price Target | 7.38 (+222.27%) |
| Earnings Date | Nov 12, 2025 |
About IRD
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutation... [Read more]
Financial Performance
In 2024, Opus Genetics's revenue was $10.99 million, a decrease of -42.30% compared to the previous year's $19.05 million. Losses were -$57.53 million, 476.1% more than in 2023.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for IRD stock is "Strong Buy." The 12-month stock price target is $7.38, which is an increase of 222.27% from the latest price.
News
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
The trial is funded through Abu Dhabi's Healthcare Research and Innovation Fund Clinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026 MERTK-related retinitis pigmentosa a...
Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
- Multi-asset pipeline with significant targeted data readouts and milestones - - Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 - - Supplemental New Dr...
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therap...
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
RESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to ...
Opus Genetics to Participate in Upcoming Investment Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease community Initial data expected in Q1 2026 RESEARCH TRIANGLE PARK, ...
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
- Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision - - Successful FDA RMAT meeting provides the poten...
Opus Genetics Announces $23 Million Registered Direct Offering
- Financing led by Perceptive Advisors and Balyasny Asset Management - - Proceeds targeted to fund rapid development of ophthalmic gene therapy clinical programs - RESEARCH TRIANGLE PARK, N.C., Nov. 0...
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides the potential for an accelerated regulatory pathway to approval of OPGx-LCA5 First participant enrolled in run-in period for p...
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited r...
Opus Genetics, Inc. - Special Call
Opus Genetics, Inc. - Special Call Company Participants Jenny Kobin George Magrath - CEO & Director Sally Tucker Conference Call Participants Debanjana Chatterjee - JonesTrading Institutional Services...
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities Lasting, durable responses obs...
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases ...
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therap...
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc.
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq:IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited re...
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
– Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinic...
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Ad...
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited r...
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
Collaboration aims to accelerate development of OPGx-RDH12, a gene therapy for RDH12-associated Leber congenital amaurosis (RDH12-LCA) RESEARCH TRIANGLE PARK, N.C., July 23, 2025 (GLOBE NEWSWIRE) -- O...
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited r...